Association between a novel polymorphism in the promoter region of the neuropeptide Y gene and schizophrenia in humans.
Hypoactivity of neuropeptide Y (NPY) is thought to be involved in the pathophysiology of schizophrenia, because post-mortem brain studies revealed a decrease of the NPY in schizophrenia, and antipsychotic treatments increase the NPY in animal brains and in cerebrospinal fluid of patients. We performed genetic analysis of the NPY gene in schizophrenia. Mutation screening of the gene detected nine single nucleotide polymorphisms, of which we typed a -485C>T variation from potential functional relevance. The -485T allele was overly represented in the disease group (P=0.0043). An in vitro promoter assay revealed that a C to T change at nt -485 significantly reduced transcriptional activity. These results suggest that the -485T allele in NPY may confer susceptibility to schizophrenia by decreasing the neuropeptide in brains.
Itokawa
Masanari
M
Department of Schizophrenia Research, Tokyo Institute of Psychiatry, 2-1-8 Kamikitazawa, Setagaya, 156-8585, Tokyo, Japan. mitokawa@prit.go.jp
Arai
Makoto
M
Kato
Shuhei
S
Ogata
Yoko
Y
Furukawa
Aizo
A
Haga
Seiichi
S
Ujike
Hiroshi
H
Sora
Ichiro
I
Ikeda
Kazuhiko
K
Yoshikawa
Takeo
T
D020022:Genetic Predisposition to Disease; D006801:Humans; D009478:Neuropeptide Y / Q000235:genetics*; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D012559:Schizophrenia / Q000235:genetics*
D009478:Neuropeptide Y